Lv41
550 积分 2023-05-12 加入
Opportunities and limitations of B cell depletion approaches in SLE
11天前
已完结
Evolution and trajectory of B-cell targeted therapies in rheumatic diseases
11天前
已完结
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?
11天前
已完结
嵌合抗原受体T细胞治疗难治性神经系统自身免疫性疾病专家共识（2025年版）
11天前
已完结
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma
11天前
已完结
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
11天前
已完结
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
11天前
已完结
Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor–T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)
12天前
已完结
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
12天前
已完结
Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) With Lenalidomide (R) Maintenance Versus R Maintenance Alone in Adult Patients With Newly Diagnosed Multiple Myeloma (NDMM) Who Have Suboptimal Response to Autologous Stem Cell Transplantation (ASCT): Phase 3 KarMMa-9 Trial
12天前
已关闭
皖公网安备34019202002308
